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dynamic incremental cost-effectiveness ratio (ICER), at the time of market entry 
and by year thereafter. While experts were not aware of any existing guidelines, 
the predominant view was that although using the brand price for the studied drug 
would be a conservative approach, it is reasonable to account for price reductions 
after patent expiration for all drugs considered. ConClusions: Drug price vari-
ations may introduce a source of uncertainty in CEA, as both timing of entry and 
level of generic drug pricing are unknown. There is currently no consensus on how 
this should be considered. Failure to incorporate generic drug entry in CEA is likely 
to yield overestimates of ICER for treatments used over long-term.
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objeCtives: Since the results of a cost-effectiveness analysis (CEA) are generally 
sensitive to the input cost parameter values selected for difference disease-related 
outcomes a systematic approach should be used to derive these estimates as sug-
gested in HTA guidance. To determine the extent to which a systematic approach 
was used to select disease-related cost estimates for inclusion in CEAs for new 
hepatitis C treatments. Methods: A systematic literature review of primary cost-
ing studies and of the cost data used in published CEAs was performed for differ-
ent stages of liver disease for those with chronic hepatitis C infection. The process 
described in the cost-effectiveness analyses by which they selected the input 
base-case cost values as well as the ranges used in the sensitivity analyses was 
reviewed to determine whether or not a systematic approach was used to identify 
primary cost studies and whether or not the a rationale was supplied for the val-
ues selected. Results: The hepatitis C systematic review focused on US costs and 
cost-effectiveness analyses. In most of the hepatitis C cost-effectiveness analyses, 
the cost estimates used were either taken directly or derived from recent primary 
cost studies. However, a systematic review was not generally used to identify the 
recent primary cost studies. In addition, the method used to adapt the data from 
the selected studies for use in the CEA was either not explained and/or appeared to 
be incorrect in some of the CEAs. In most of the CEAs, sensitivity analyses assumed 
arbitrary ranges for the cost estimates (for example, plus or minus 50%) rather than 
using ranges from alternative cost studies. ConClusions: Very little detail is pro-
vided in published CEAs about the methods used to identify primary disease-related 
cost studies and a rationale for selection of the costs is generally not provided.
PRM31
idEntifying thE BRoadER valuE of vaCCinEs in low and MiddlE inCoME 
CountRiEs
Van der Putten I.M.1, Hiligsmann M.1, Paulus A.T.G.1, Hutubessy R.2, Evers S.M.1
1Maastricht University, Maastricht, The Netherlands, 2World Health Organization, Geneva, 
Switzerland
objeCtives: Current economic evaluations of vaccine immunization strategies 
mainly concentrate on immediate health gains (measured in metrics such as 
QALYs or DALYs) and household cost savings. Vaccine immunization strategies, 
however, often take place within a broader societal context. In order to finan-
cially sustain these strategies, economic evaluations should not only encompass 
immediate health gains and household costs but also the ‘broader value of vac-
cines’. This study aims to identify the relevance of information with regard to 
the broader value of vaccines for decision makers in low and middle income 
countries. Methods: Several methods were used to identify the broader value 
of vaccines including a literature review, a survey, interviews and consultations 
with experts. The long-term effects of those who were vaccinated and the effects 
experienced by society as a whole, including non-vaccinated community mem-
bers, were included in a framework. Results: In total, twenty broader values 
in five different domains were identified. The first domain included long-term 
productivity gains. These gains refer to the individual long-term productivity due 
to better physical and mental health as well as to the economic consequences of 
decisions made by households due to improved child survival. The second domain 
consists of ecological values which are related to the decline of prevalence and 
incidence of vaccine related diseases. The third domain encompasses different 
types of equity considerations. The fourth domain includes the impact of vaccine 
strategies on other health interventions. Finally, the fifth domain includes macro-
economic effects, such as the impact of vaccine immunization strategies on GDP 
tax revenues and overall government savings. ConClusions: Several broader 
economic values outside the health care sector were identified. These results 
provide the input for the incorporation of these values in economic evaluations. 
Further research is needed to identify the most important broader values for 
national decision makers.
PRM32
PRoPosal foR a CoMPREhEnsivE dEfinition of BudgEt iMPaCt analysis
Bierbaum M.
Friedrich-Alexander-Universität Erlangen-Nürnberg, Nuremberg, Germany
objeCtives: To our knowledge in most articles BIA is only defined as what it does. 
Some authors have tried to define it by comparing it to cost effectiveness analysis. But 
still there is no common stand-alone definition of the term Budget Impact Analysis 
available. Our aim is to provide such a definition. Methods: In the course of a PhD 
thesis we conducted a systematic literature review in order to identify methodo-
logical articles regarding budget impact analyses. We searched pudmed and seven 
other databases to identify relevant articles. From the eligible articles the different 
understandings and definitions of BIA were extracted and synthesized into a compre-
hensive definition. Results: Our search delivered 223 articles from which 28 met our 
inclusion criteria. 15 different approaches to describe BIAs were identified. Over the 
years (2001 to today) there was a constant improvement and increase of complexity 
in the descriptions. Nevertheless most of the late definitions are based on the work of 
set appears reasonably valid for research, particularly following accreditation. The 
dataset may be a suitable alternative to collecting MR data manually within a trial, 
although caution should be exercised with earlier data. Further work is ongoing to 
establish the nature of the missing data and the implications for cost differences.
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objeCtives: To determine whether giving patients a resource use log (RUL) at 
hospital discharge reduces recall bias in a follow-up resource use questionnaire 
(RUQ). Methods: Within the APEX randomised controlled trials (RCTs), 86 patients 
undergoing joint replacement were randomised to receive or not receive an RUL at 
hospital discharge (The RUL trial). A postal RUQ was then administered to all par-
ticipants at 3-months after surgery. Resource use data (visits to GPs, GP home visits 
and telephone calls; GP practice nurse visits and telephone calls; and prescribed 
medication) in relation to the patient’s joint replacement were extracted from GP 
records from hospital discharge until completion of the 3-month RUQ by a blinded 
researcher. Data from both sources were coded into use of resource and number 
of contacts. For each resource use category, descriptive statistics were calculated 
by data source and RUL trial arm. Kappa statistics and Concordance Correlation 
Coefficients (CCC) were calculated as appropriate. Results: GPs were contacted 
for 67/86 patients originally randomised to receive or not receive an RUL (one had 
surgery delayed, 3 died, 5 withdrew, 6 had GP practices outside of area, 4 did not 
complete the 3-month RUQ). Information was then extracted for 66/67 patients. 
There was evidence of improved recall in favour of the RUL arm in relation to visiting 
a GP (Kappa= 0.5312 vs. -0.0161). There was some slight evidence in favour of the 
non-RUL arm with regards to having a GP home visit (Kappa= 0.335 vs. -0.0937). The 
RUL arm showed more agreement than the non-RUL arm between data sources 
in terms of number of: visits to GPs (CCC= 0.581 vs. -0.013); GP telephone calls 
(CCC= 0.564 vs. 0.173) and prescriptions (CCC= 0.418 vs. -0.13). ConClusions: 
Although based on small numbers, our study found some evidence that provision 
of an RUL reduces recall bias in relation to visits to GPs.
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objeCtives: Several new disease modifying therapies have recently received mar-
keting authorisations for the treatment of relapsing-remitting multiple sclerosis 
(RRMS). Given the recent appraisal by NICE of these therapies, the objective of this 
study was to systematically review and critically evaluate the techniques used in 
modelling relapsing-remitting multiple sclerosis in the UK. Methods: Embase, 
Medline, Cochrane Library and the NICE website were searched systematically on 
03.03.14 to identify articles relating to cost-utility models in RRMS with a UK per-
spective. Data sources, techniques and assumptions of the included models were 
extracted, compared and critically evaluated. Results: Of 385 search results, 25 full 
texts were evaluated and 17 articles (relating to 12 different models) were included. 
Early models varied considerably in method and structure but convergence was 
apparent over time towards a Markov model with states based on disability score, 
a 1-year cycle length and a lifetime time horizon. More recent models also allowed 
for disability improvement within the natural history of the condition. Considerable 
variety remains, however, with an increasing number of comparators over time, the 
need for treatment sequencing and different assumptions around efficacy waning 
and treatment withdrawal. Additionally, modelling techniques were sometimes 
implemented inappropriately. Confidential data sources were frequently used, espe-
cially within the models submitted to NICE. ConClusions: Despite a convergence 
over recent years to a similar Markov structure, there are still significant discrep-
ancies between the models simulating the course of RRMS in the UK. Differing 
methods, assumptions and data sources make the comparison of models, and their 
results, problematic. The Markov structure commonly used also leads to problems 
such as an incapability to deal with heterogeneous populations and multiplying 
complexity with treatment sequences; these would best be solved by using alterna-
tive model types such as discrete event simulations.
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objeCtives: Cost-effectiveness analyses (CEA) are used to support funding deci-
sions for new drugs by estimating their clinical and economic value. While prices 
of drugs may fall over time due to market competition, entrance of generic drugs, 
or negotiated price cuts, this is rarely accounted for in CEA. The objective is to 
review pharmacoeconomic guidelines and current practice around drug price evalu-
ation in CEA. Methods: Pharmacoeconomic guidelines were reviewed to identify 
countries in which a drug price modification over the time horizon is allowed or 
recommended in CEA. Then methodological articles and published CEA using price 
modifications were identified. Finally, several health economics experts were inter-
viewed. Results: Only 3 pharmacoeconomic guidelines report recommendations 
around price adjustment in CEA (Norway, New-Zealand): modellers should take 
into account changes in drug price over time. In France, it is possible to include a 
generic price in sensitivity analysis. In other countries, this was not mentioned in 
the guidelines. Methodological articles mentioned the possibility to use an esti-
mated 4% decrease over time in UK. In most of published CEA incorporating price 
modifications, this was performed as secondary analyses. Other CEA reported 
